Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons

Biochimica et Biophysica Acta - Bioenergetics

Volumn 1797, Issue 6-7, 2010, Pages 1178-1188

  Misiak, Magdalena ^a   Beyer, Cordian ^a   Arnold, Susanne ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Estrogen; Gender; Mitochondria; Neuron; Oxidative stress; Parkinson's disease

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME C OXIDASE; DOPAMINE; LACTATE DEHYDROGENASE; MITOCHONDRIAL PROTEIN; OXIDOPAMINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; FEMALE; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MALE; MESENCEPHALON; MITOCHONDRION; MOUSE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL DEATH; CELLS, CULTURED; DNA PRIMERS; DOPAMINE; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ESTRADIOL; FEMALE; GENE EXPRESSION; MALE; MESENCEPHALON; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MODELS, NEUROLOGICAL; NECROSIS; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; SEX CHARACTERISTICS;

PARKINSONIA;

EID: 77953872839     PISSN: 00052728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbabio.2010.04.009     Document Type: Article

References (61)

1. van den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
2. Dluzen D.E., McDermott J.L. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J. Gend.-Specif Med. 2000, 3:36-42.
3. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1:139-154.
4. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 2004, 75:637-639.
5. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., Booij J., Dluzen D.E., Horstink M.W. Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:819-824.
6. Ragonese P., D'Amelio M., Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann. NY Acad. Sci. 2006, 1089:373-382.
7. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., Melton Iii L.J. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 103:98-114.
8. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
9. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
10. Banerjee R., Starkov A.A., Beal M.F., Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 2009, 1792:651-663.
11. Andreyev A.Y., Kushnareva Y.E., Starkov A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc.) 2005, 70:200-214.
12. Cohen G., Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 1974, 249:2447-2452.
13. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, related compounds toward C1300 neuroblastoma cells in vitro. Mol. Phamacol. 1978, 14:644-653.
14. Glinka Y., Youdim M.B.H. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 1995, 292:329-332.
15. Tamás A., Lubics A., Lengvári I., Reglodi D. Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease. Endocrine 2006, 29:275-287.
16. Braak H., Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat. Med. 2008, 14:483-485.
17. Schmidt U., Pilgrim U., Beyer C. Differentiative effects of dopamine on striatal neurons involve stimulation of the cAMP/PKA pathway. Mol. Cell. Neurosci. 1998, 11:9-18.
18. Decker D.E., Althaus J.S., Buxser S.E., von Voigtlander P.F., Ruppel P.L. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res. Commun. Chem. Pathol. Pharmacol. 1993, 79:195-208.
19. Lotharius J., Dugan L.L., O'Malley K.L. Distinct mechanisms underlie neurotoxin mediated cell death in cultured dopaminergic neurons. J. Neurosci. 1999, 19:1284-1293.
20. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl Acad. Sci. USA 2005, 102:19126-19131.
21. Simpkins J.W., Yi K.D., Yang S.H., Dykens J.A. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta 2009, 10.1016/j.bbagen.2009.11.013.
22. Ramsay R.R., Singer T.P. Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piercidin A, and MPP1. Biochem. Biophys. Res. Commun. 1992, 189:47-52.
23. White R.J., Reynolds I.J. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J. Neurosci. 1996, 16:5688-5697.
24. Huerta C., Castro M.G., Coto E., Blázquez M., Ribacoba R., Guisasola L.M., Salvador C., Martínez C., Lahoz C.H., Alvarez V. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J. Neurol. Sci. 2005, 236:49-54.
25. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 2007, 104:1325-1330.
26. Saikumar P., Ramakrishna Kurup C.K. Effect of administration of 2-methyl-4-dimethylaminoazobenzene on the half-lives of rat liver mitochondria and cytochrome c oxidase. Biochim. Biophys. Acta 1985, 840:127-133.
27. Villani G., Greco M., Papa S., Attardi G. Low reserve of cytochrome c oxidase capacity in vivo in the respiratory chain of a variety of human cell types. J. Biol. Chem. 1998, 273:31829-31836.
28. Arnold S., Kadenbach B. Cell respiration is controlled by ATP, an allosteric inhibitor of cytochrome c oxidase. Eur. J. Biochem. (FEBS J.) 1997, 249:350-354.
29. Arnold S., Kadenbach B. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. FEBS Lett. 1999, 443:105-108.
30. Kadenbach B., Arnold S. A second mechanism of respiratory control. FEBS Lett. 1999, 447:131-134.
31. Horvat S., Beyer C., Arnold S. Effect of hypoxia on the transcription pattern of subunit isoforms and the kinetics of cytochrome c oxidase in cortical astrocytes and cerebellar neurons. J. Neurochem. 2006, 99:937-951.
32. Singh S., Misiak M., Beyer C., Arnold S. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes. Glia 2009, 57:1480-1491.
33. Pellerin L. Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem. Int. 2003, 43:331-338.
34. Folbergrová J., Ješina P., Haugvicová R., Lisỳ V., Houštěk J. Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem. Int. 2010, 56:394-403.
35. Klawitter J., Anderson N., Klawitter J., Christians U., Leibfritz D., Eckhardt S.G., Serkova N.J. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br. J. Cancer 2009, 100:923-931.
36. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
37. Marella M., Seo B.B., Nakamaru-Ogiso E., Greenamyre J.T., Matsuno-Yagi A., Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 2008, 3:e1433.
38. Davidson C., Gow A.J., Lee T:.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. 2001, 36:1-22.
39. Arnold A.P., Gorski R.A. Gonadal steroid induction of structural sex differences in the central nervous system. Annu. Rev. Neurosci. 1984, 7:413-442.
40. McEwen B.S. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997, 48:8-15.
41. Reisert I., Han V., Lieth E., Toran-Allerand D., Pilgrim C., Lauder J. Sex steroids promote neurite growth in mesencephalic tyrosine hydroxylase immunoreactive neurons in vitro. Int. J. Dev. Neurosci. 1987, 5:91-98.
42. Ma Z.Q., Spreafico E., Pollio G., Santagati S., Maggi A. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc. Natl Acad. Sci. USA 1993, 90:3740-3744.
43. Agrati P., Ma Z.Q., Patrone C., Picotti G.B., Pellicciari C., Maggi A. Dopaminergic phenotype induced by estrogens in a human neuroblastoma cell line. Eur. J. Neurosci. 1997, 9:1008-1016.
44. Beyer C., Karolczak M. Estrogenic stimulation of neurite growth in midbrain dopaminergic neurons depends on cAMP/ protein kinase A signalling. J. Neurosci. Res. 2000, 59:107-116.
45. Sawada H., Shimohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci. Biobehav. Rev. 2000, 24:143-147.
46. Ivanova T., Beyer C. Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain. J. Neurobiol. 2003, 54:638-647.
47. Kishi Y., Takahashi J., Koyanagi M., Morizane A., Okamoto Y., Horiguchi S., Tashiro K., Honjo T., Fujii S., Hashimoto N. Estrogen promotes differentiation and survival of dopaminergic neurons derived from human neural stem cells. J. Neurosci. Res. 2005, 79:279-286.
48. Kipp M., Karakaya S., Pawlak J., Araujo-Wright G., Arnold S., Beyer C. Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. Front. Neuroendocrinol. 2006, 27:376-390.
49. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997, 767:340-344.
50. Bains M., Cousins J.C., Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 2007, 204:767-776.
51. Bettini E., Maggi A. Estrogen induction of cytochrome c oxidase subunit III in rat hippocampus. J. Neurochem. 1992, 58:1923-1929.
52. Chen J., Delannoy M., Odwin S., He P., Trush M.A., Yager J.D. Enhanced mitochondrial gene transcript, ATP, Bcl-2 protein levels, and altered glutathione distribution in ethinyl estradiol-treated cultured female rat hepatocytes. Toxicol. Sci. 2003, 75:271-278.
53. Scheller K., Sekeris C.E. The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation. Exp. Physiol. 2003, 88:129-140.
54. Araújo G.W., Beyer C., Arnold S. Oestrogen influences on mitochondrial gene expression and respiratory chain activity in cortical and mesencephalic astrocytes. J. Neuroendocrinol. 2008, 20:930-941.
55. Arnold S., de Araújo G.W., Beyer C. Gender-specific regulation of mitochondrial fusion and fission gene transcription and viability of cortical astrocytes by steroid hormones. J. Mol. Endocrinol. 2008, 41:289-300.
56. Irwin R.W., Yao J., Hamilton R.T., Candenas E., Brinton R.D., Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008, 149:3167-3175.
57. Wang T.T., Phang J.M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995, 55:2487-2489.
58. Garcia-Segura L.M., Cardona-Gomez P., Naftolin F., Chowen J.A. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998, 9:593-597.
59. Chen J., Li Y., Lavigne J.A., Trush M.A., Yager J.D. Increased mitochondrial superoxide production in rat liver mitochondria, rat hepatocytes, and HepG2 cells following ethinyl estradiol treatment. Toxicol. Sci. 1999, 51:224-235.
60. Wang J., Green P.S., Simpkins J.W. Estradiol protects againstATP, depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J. Neurochem. 2001, 77:804-811.
61. Arnold S., Beyer C. Neuroprotection by estrogen in the brain: the mitochondrial compartment as presumed therapeutic target. J. Neurochem. 2009, 110:1-11.